According to a new study published in Cancer Cell, booster shots of COVID-19 vaccines evoked immune responses in cancer patients who did not have any detectable antibodies after the primary vaccination.

It was noted that in seronegative patients, a third vaccine dose led to a seroconversion rate of 56%. Investigators evaluated the anti-COVID immunity before and after a booster dose in 88 patients with cancer (31 with solid tumors and 57 with hematologic malignancies). About 73% of these were on active treatment at the time of receiving a booster shot. Nearly 64% of the patients were seropositive before the booster shot, while 36% were seronegative and all seronegative patients, except one, had hematologic malignancies. Four weeks following the booster jab, 70 of the 88 patients (80%) were found to have antibody levels higher than the levels prior to receiving the booster… (Medpage Today)